NCT05569421 - A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

April 14, 2023

Study Completion Date

April 14, 2023

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Treatment A: BGF MDI HFO

Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.

DRUG

Treatment B: BGF MDI HFA

Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.

Trial Locations (1)

Research Site, Glendale